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Abstract
Introduction Central line-associated bloodstream
infections (CLABSI) are the most important cause of
morbidity and mortality in critically ill patients. Evidencebased interventions when used in form of a bundle have
proven to decrease CLABSI. Our unit has a high CLABSI
rate (9/1000 central line days). Therefore, we intend to
introduce evidence-based CLABSI prevention package in
our practice to improve CLABSI rates in our NICU within
limited resources.
Methods and analysis The study will be conducted
using preanalysis and postanalysis design from January
2016 to December 2017. It is going to be conducted in
three phases with phase I being the preimplimentation
phase where retrospective data will be collected. Phase
II, implementation phase, where the CLABSI prevention
package will be introduced and phase III will be follow-up
to see the impact. Primary outcome will be reduction in
CLABSI rates.
Analysis plan and reporting For all three phases,
descriptive analysis will be performed. Nominal data will
be presented as mean±SD, whereas categorical data will
be presented as frequencies and percentages. To compare
the effect of intervention we will use independent sample
t-test for continuous outcomes, whereas Χ2 test will be
used for categorical outcomes. Relative risk ratios, 95% CI,
and p values will be determined. Incidence density will
be calculated and Poisson regression will be used to
determine factors associated with incidence of CLABSI.
Microbiological profiles and antimicrobial resistance
pattern will be reported as pan sensitive, multidrugresistant organism and carbapenem-resistant organism.
SQUIRE V.2.0 guidelines will be used for manuscript writing
and reporting.
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Introduction
Healthcare-associated infections (HAI) are
a major problem worldwide.1Among HAI,
central line-associated bloodstream infections (CLABSI) are the most important
cause of morbidity, mortality and prolonged
hospital stay, especially in critically ill

What is already known about this subject?
►► CLABSI is defined as a LCBI (Laboratory confirmed

blood stream infection) where central line was in
place for greater than two calendar days on the
date of the event, with day of device placement
being day one, and the line was also in place on the
date of the event or the day before.
►► In developing countries CLABSI is either un
addressed or under reported
►► Interventions for reduction of CLABSI when used in
form of bundles have proven to be efficacious.

What this study hopes to achieve?
►► If successful this can be used at a larger scale for

CLABSI prevention both within our institution and
other facilities worldwide.
►► It might be helpful to understand the spectrum of
microorganisms and their antimicrobial resistance.

patients.2 Risk of neurodevelopmental
impairment significantly increases with one
or more episodes of HAI in very low birthweight infants.3 Although a 46% decrease in
CLABSI has occurred in hospitals across the
USA from 2008 to 2013, an estimated 30 100
CLABSI still occur in intensive care units
(ICU) and wards of the USA.4 Due to many
factors in low-resource countries, CLABSI
are either unaddressed or under-reported,
meaning that the impact of CLABSI-related mortality and morbidity may be much
higher than what is reported. In a review
of literature, neonatal intensive care unit
(NICU) CLABSI rates ranged from 2.6 to 60
cases per 1000 central line days in limited-resource countries in comparison with 2.9
cases per 1000 central line days in the USA.5
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Since Pronovost et al landmark paper in 2006 indicating the usefulness of central line insertion bundles
in reducing CLABSI,6 significant amount of research
has led to implementation of line insertion and maintenance bundles in ICU worldwide leading to significant
reduction in CLABSI rates. A recent systemic review
and meta-analysis showed a risk reduction in CLABSI
incidence from 6.4 per 1000 catheter days to 2.5 per
1000 catheter days after implementation of these
bundles. Significantly higher risk reduction were also
noted in studies having baseline incidence rates of 5 per
1000 catheter days or greater.7 A healthcare bundle is
defined as a small, straightforward set of evidence-based
practices that, when performed collectively and reliably, have been proven to improve patient outcomes.8
Merging several evidence-based catheter care practices
into one system increases chances of its adherence and
eventual success.
Our unit at the Aga Khan University Hospital (AKUH)
is a leading tertiary care private sector teaching hospital
located in Karachi, Pakistan with a 24-bedded level 3
NICU. We have four bays of five cots each along with
four isolation rooms. We admit approximately 800–1000
patients per year including those born at AKUH and its
affiliated hospitals along with those who are transferred
from outside hospitals. Our nurse-to-patient ratio is
usually 1:2 for non-infected patients and 1:1 for culture
proven infections. Our hospital has an infection control
team which comprises trained infection control nurses
and an infectious disease physician. These, along with a
dedicated neonatologist, prospectively classify CLABSI
according to the US Centers for Disease Control's
(CDC) National Health and Safety Network criteria.9
Qadir et al10 from our NICU have reported a sustained
reduction in multidrug-resistant bloodstream infection (BSI) by using simple evidence-based strategies,
which included hand washing certification for all staff,
use of chlorhexidine instead of povidone iodine for
skin preparation, use of non-sterile gloves for diaper
change, implementation of barrier nursing for clinically suspected and culture-proven infections, provision
of separate intubation and central line trolley for each
room and limiting the use of umbilical catheters to 7
days. These interventions and data are from June 2010
to December 2011. Since then, our utilisation of central
lines, especially peripherally inserted central catheters
(PICC) has increased due to awareness of its utility but
simultaneously our CLABSI rates have climbed high. Our
NICU CLABSI rates have been around 9/1000 central
line days over the last 5 years (2011–2015), with a line
utilisation ratio of 0.36. Approximately 60% of our
CLABSI are Gram-negative organisms, which are mostly
MDR organisms (MDRO) (unpublished data).
Since 2014, we have gradually moved from 12-bedded
facility to a 24-bedded unit to accommodate the increasing
number of deliveries and referrals. With this increase in
bed space, and our high CLABSI rates, it became imperative to initiate a quality improvement programme to
2

reduce CLABSI rates. Therefore, we intend to introduce
an evidence-based CLABSI prevention package (CPP)
to improve CLABSI rates in our NICU within limited
resources.
Objectives: We intend to implement a quality improvement programme by introducing evidence-based CPP
and measure its impact on CLABSI rates.
Study design: Preanalysis and postanalysis design using
PDCA (Plan DoCheck Act)model.
Settings: AKUH NICU.
Duration:Twelve months (from 1 January2017 to 31
December 2017).
Inclusion criteria
All patients admitted to AKUH NICU from 1 January 2016
to 31 December 2017, who have central line in place.
Operational definitions
1. Central line: a catheter that ends at or close to heart
or in any of the great vessels and is to be used for
haemodynamic monitoring, infusions and blood
sampling. The following will be considered great
vessels: aorta, superior vena cava, inferior vena
cava, brachiocephalic or innominate veins, internal
jugular veins, subclavian veins, external iliac veins
and common femoral veins. Central lines that will
be included are PICC line, Umbilical arterial and
venous lines and central venous line, which includes
tunnelled and cuffed or non-tunnelled femoral lines.
2. Laboratory-confirmed bloodstream infection (LCBI):
LCBI will be defined as:
a. A patient with a recognised pathogen cultured
from one or more blood cultures, where the
organism cultured was not related to an infection
at another site; or
b. A patient found to have a common skin
(eg,
coagulase-negative
contaminant
staphylococci, viridans group streptococci
or micrococci, diphtheroids, Bacillus sp,
Propionibacterium sp) cultured from two or more
blood cultures and one or more of the following
signs or symptoms: fever >38°C, hypotension or
hypothermia <37°C, apnoea or bradycardia and
where signs, symptoms and positive laboratory
results were not related to an infection at another
site.
3. CLABSI: according to the CDC, CLABSI is defined
as an LCBI where central line or umbilical catheter
(UC) was in place for >2 calendar days on the date
of the event, with day of device placement being on
day 1, and the line was also in place on the date of the
event or the day before. For this study, only the first
CLABSI will be included for a particular line.
4. Device days: total number of days of exposure to device (central line) by all patients in NICU.
5. CLABSI rates: total number of CLABSI divided by the
total number of device days 1000.
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Device utilisation ratio: proportion of patients for
which device is used, that is, number of device days/
number of patient days 100.
7. Pan-sensitive microorganisms: those organisms that
are sensitive to all first-line antibiotics.
8. MDRO: multidrug resistance is defined as resistance
(R) to at least one agent in three or more tested antimicrobial categories.
9. Carbapenem resistance: it is defined as a result of
intermediate (I) or R to imipenem or meropenem.
Methodology and data collection
The study will be performed in three phases.
Phase I: preimplimentation phase
In this phase, all patients from 1 January 2016 to 31
December 2016, with central line in place for >2 calendar
days, with the day of line placement as day 1, will be
enrolled.
Patient days, device days, CLABSI rates, line utilisation ratio and hand hygiene compliance over the past 12
months (January–December 2016) will be retrieved from
the hospitals infection control data base.
Phase II: implementation phase
In this phase, evidence-based CPP will be introduced
from 1 January 2017 to 31 March 2017. All patients with
central line in place for >2 calendar days, with day of line
placement as day 1, will be enrolled and followed-up until
either transfer from NICU to step-down unit, discharge
or death.
Phase III: follow-up phase
In this phase, all patients from 1 April 2017 to 31 December
2017, with central line in place for >2 calendar days with
day of device placement as day 1, will be enrolled and
followed-up until either transfer from NICU to step-down
unit, discharge or death.
Prospectively collected data regarding patient days,
device days, device utilisation ratio and CLABSI rates will
be obtained from hospital infection control surveillance
data bases monthly and recorded on a separate excel
sheet.
In addition, a team composed of an attending neonatologist, NICU infection control nurse and infection
control team would review the patients in the NICU and
check the CLABSI cases submitted to ensure data quality.
All data will be collected by a NICU fellow not involved
in the CPP.
The following data will be recorded for all patients:
data regarding gestational age, chronological age, birth
weight and current weight, place of birth, length of
NICU stay, brief clinical summary along with date, time
and reason for removal will be recorded. Dwell time
for each line will also be recorded. Total days of parenteral nutrition will also be recorded. Device day at which
CLABSI is confirmed will also be noted. Microorganisms
will be identified and antibiotic susceptibility profiles will

be obtained from laboratory reports and recorded on a
predefined proforma. Susceptibility results are usually
reported using the category interpretations of susceptible, I, R or not tested. Microorganisms will be classified
on the basis of their sensitivity patterns into pan-sensitive,
MDRO and carbapenem-resistant organism (CRO).
CPP proforma is shown in online supplementary file.
After a literature search, the following evidence-proven
interventions have been identified for reducing CLABSI
rates in NICU, which will be implemented over a period
of 3 months (Phase II):
1. Hand hygiene
a. Repeated reminders by regular hand hygiene
week and champion of the month award11 (IA)i;
b. Non-sterile gloves for routine handling of babies
<1000 g12 (IA)i.
2. Central line insertion
a. Hand hygiene with hospital-approved alcoholbased product or antiseptic-containing soap
before and after palpating insertion sites and
before and after inserting central line13–15 (IA)i;
b. Use of maximal barrier precautions (including
sterile gown, sterile gloves, surgical mask, hat and
large sterile drape)13 16 (IA)i;
c. Disinfect skin with appropriate antiseptic (eg,
2% chlorhexidine, 70% alcohol) before catheter
insertion13 17 18 (IA)i;
d. Use either a sterile transparent semi-permeable
dressing or sterile gauze to cover the insertion
site19–21 (IA)i;
e. Central
line
insertion
certification
of
physicians22–24 (IB)i;
f. Reinforcement of central line kit and
implementation of dressing/readjustment kit25
(IA)i;
g. Elective central line insertions at day time.
3. Central line maintenance
a. Closed medication system and two person process
for all dressing change and tubing change26 (IB)i;
b. Perform hand hygiene with hospital-approved
alcohol-based product or antiseptic-containing
soap before and after accessing a catheter or
changing the dressing13–15 (IA)i;
c. Maintain aseptic technique when changing
intravenous tubing and when entering the
catheter including ‘scrub the hub’20 25 27 (IA)i;
i

Ranking system for evidence according to the CDC/Healthcare
Infection Control Practice Advisory Committee System: category
IA: strongly recommended for implementation and strongly
supported by well-designed experimental, clinical or epidemiological studies. Category IB: strongly recommended for implementation and supported by some experimental, clinical or
epidemiological studies and a strong theoretical rational. Category IC: required for implementation, as mandated by federal
and/or state regulation or standard. Category II: suggested for
implementation and supported by suggestive clinical or epidemiological studies or a theoretical rationale or a consensus by a
panel of experts.

Hussain ASshabbir, et al. BMJ Paediatrics Open 2017;1:e000008. doi:10.1136/bmjpo-2017-000008

3

Downloaded from http://bmjpaedsopen.bmj.com/ on April 19, 2018 - Published by group.bmj.com

Open Access
d. Evaluate the catheter insertion site daily for signs
of infection and to assess dressing integrity. At
a minimum, if the dressing is damp, soiled or
loose, change it aseptically and disinfect the skin
around the insertion site with an appropriate
antiseptic18 20 27 28 (IB)i;
e. Daily review of catheter necessity with prompt
removal when no longer essential13 29 (IB)i ii;
f. Minimising the access points30 (IA)i ii;
g. Heprin in TPN (0.5 Units/mL)31 (IA)i ii.
4. Organism-specific prevention (fungal infections):
a. Fluconazole prophylaxis for babies <1000 g
(intravenous fluconazole 6 mg/kg/dose after
every 2 days)32 (IA)i;
b. Minimise the use of H2 receptor blocker and
proton pump inhibitor33 (II)i;
c. Minimise the use of broad-spectrum antibiotics34
(II)i.
5. Nurse empowerment35
a. Nurse empowerment will be the cornerstone of
the project. A dedicated infection control NICU
nurse will be identified and empowered to take
charge of the overall implementation of CPP.
b. Her/his responsibilities will be as follows:
i. Collect and record daily patient days, device
days and device utilisation ratio;
ii. Collect and record all infections in NICU;
iii. Twice monthly meeting with hospitals
infection control team to identify CLABSI
from the BSI;
iv. Daily assessments of all central line insertion
checklists for completeness and deficiencies;
v. Daily feedback to concerned physician and
nurse regarding deficiencies in central line
insertion and maintenance;
vi. Ensure hand hygiene is practised and its
compliance is 100%;
vii. Ensure all components of evidence-based
CPP are practised;
viii. Monthly reporting of data to NICU faculty
and quarterly to service line chief.

weight, gestational age, length of hospital stay, catheter
dwell time and TPN days will be presented as mean±SD.
Categorical data like source of admission, outcomes,
birth weight and gestational age categories, diagnosis,
catheter type will be presented as frequencies and
percentages.
To compare the effect of intervention, we will use independent sample t-test for continuous outcomes, whereas
Χ2 test will be used for categorical outcomes. Relative risk
ratios, 95% CIs and p values will be determined for all
outcomes. Probability values <0.05 using two-sided tests
will be considered significant. Incidence density will be
calculated and Poisson regression will be used to determine factors associated with incidence of CLABSI. Microbiological profiles and their antimicrobial resistance
pattern will be reported as pan sensitive, MDRO and
CRO. We will use SQUIRE V.2.0. Guidelines for reporting
our findings.36

Discussion and conclusion
CPP is designed to improve the quality of care by reducing
CLABSI in our unit. The project will help in identifying
and comparing the risk factors for development of
CLABSI and the impact of evidence-based interventions
in reducing it. It will also help in understanding the spectrum of microorganisms related to the development of
CLABSI and their antimicrobial resistance patterns.
We feel confident that we will be able to achieve this
by meticulous implementation and monitoring of this
programme. This research will shed light on the extent of
this unaddressed and under-reported problem, especially
in our part of the world and will possibly find cost-effective solutions which will lead to long-term changes in our
NICU protocols and may be helpful for other similar
units in low-income countries.
Contributors ASsH and SRA conceptualised and wrote the initial draft. SA
reviewed and revised the manuscript. ASsH, SA,SD and JZ contributed to the
development and implementation of the study interventions. AR contributed to the
study design and analysis plan. All authors contributed equally in the final approval
of the submitted version of the manuscript.
Competing interests None declared.

Outcomes, analysis plan, results and reporting
Our primary outcome is CLABSI rates following implementation of our QI programme. Secondary outcomes
may show a decrease in line utilisation ratio, improved
hand hygiene compliances and reduction in fungal
infections. We also intend to demonstrate microorganism profiles and their antimicrobial resistance
patterns.
Final analysis will be done on SPSS V.22.
For all three phases, descriptive analysis will be
performed for all variables. Nominal data like age,
ii

Points d, e and f will be reviewed daily by using sticker
(attached).
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